An autosomal recessive disorder, Ataxia Telangiectasia, affects a person's nervous system, immune system, along with the other body parts. The disease causes difficulties in coordinating movements beginning in early childhood, usually before the age of 5.
A result of a mutation in the ATM gene, Ataxia Telangiectasia, approximately affects one in 40,000 – 100,000 live births in the US.
Know more about the Ataxia Telangiectasia, its pathophysiology, manifestations, epidemiological scenario, and available treatment modalities by filling up the form towards the right.
Get insights into the Ataxia Telangiectasia market landscape, upcoming therapies, and key pharma companies transforming Ataxia Telangiectasia market outlook through our newsletter.
DelveInsight, with its new newsletter series, aims to put forward enriching content related to various rare diseases for a crystal-clear picture of the rare disease, their therapies, and market trends.
Download our newsletters and subscribe to our page to keep yourself abreast of the latest events of significance in the field.
Join DelveInsight's emailer list and gain a competitive edge.
Know more about What's covered:
- Indication overview
- Epidemiological trends
- Treatment approaches
- Key Companies
- Pipeline drugs
- R&D in the field
- Top conferences
- Support from International organizations
- Collaborations and deals in the domain